Modeling Mitochondrial DNA Diseases: from Base Editing to Pluripotent Stem-cell-derived Organoids

Overview

Journal EMBO Rep

Specialty Molecular Biology

Date 2023 Mar 6

PMID 36876467

Authors

Isabella Tolle

Valeria Tiranti

Alessandro Prigione

Affiliations

Soon will be listed here.

Abstract

Mitochondrial DNA (mtDNA) diseases are multi-systemic disorders caused by mutations affecting a fraction or the entirety of mtDNA copies. Currently, there are no approved therapies for the majority of mtDNA diseases. Challenges associated with engineering mtDNA have in fact hindered the study of mtDNA defects. Despite these difficulties, it has been possible to develop valuable cellular and animal models of mtDNA diseases. Here, we describe recent advances in base editing of mtDNA and the generation of three-dimensional organoids from patient-derived human-induced pluripotent stem cells (iPSCs). Together with already available modeling tools, the combination of these novel technologies could allow determining the impact of specific mtDNA mutations in distinct human cell types and might help uncover how mtDNA mutation load segregates during tissue organization. iPSC-derived organoids could also represent a platform for the identification of treatment strategies and for probing the in vitro effectiveness of mtDNA gene therapies. These studies have the potential to increase our mechanistic understanding of mtDNA diseases and may open the way to highly needed and personalized therapeutic interventions.

Citing Articles

Mitochondrial diseases: from molecular mechanisms to therapeutic advances.

Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X Signal Transduct Target Ther. 2025; 10(1):9.

PMID: 39788934 PMC: 11724432. DOI: 10.1038/s41392-024-02044-3.

Disease models of Leigh syndrome: From yeast to organoids.

Henke M, Prigione A, Schuelke M J Inherit Metab Dis. 2024; 47(6):1292-1321.

PMID: 39385390 PMC: 11586605. DOI: 10.1002/jimd.12804.

Fetal and obstetrics manifestations of mitochondrial diseases.

Adelizzi A, Giri A, Di Donfrancesco A, Boito S, Prigione A, Bottani E J Transl Med. 2024; 22(1):853.

PMID: 39313811 PMC: 11421203. DOI: 10.1186/s12967-024-05633-6.

Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome.

Falabella M, Pizzamiglio C, Tabara L, Munro B, Abdel-Hamid M, Sonmezler E Brain. 2024; 148(2):647-662.

PMID: 39279645 PMC: 11788212. DOI: 10.1093/brain/awae268.

mtDNA analysis using Mitopore.

Dobner J, Nguyen T, Pavez-Giani M, Cyganek L, Distelmaier F, Krutmann J Mol Ther Methods Clin Dev. 2024; 32(2):101231.

PMID: 38572068 PMC: 10988129. DOI: 10.1016/j.omtm.2024.101231.

References

Zhang J, Liu H, Luo S, Lu Z, Chavez-Badiola A, Liu Z . Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online. 2017; 34(4):361-368. DOI: 10.1016/j.rbmo.2017.01.013. View

Cavaliere A, Marchet S, Di Meo I, Tiranti V . An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model. J Vis Exp. 2022; (181). DOI: 10.3791/63452. View

McCann B, Cox A, Gammage P, Stewart J, Zernicka-Goetz M, Minczuk M . Delivery of mtZFNs into Early Mouse Embryos. Methods Mol Biol. 2018; 1867():215-228. DOI: 10.1007/978-1-4939-8799-3_16. View

Scholle L, Zierz S, Mawrin C, Wickenhauser C, Lehmann Urban D . Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis. Genes (Basel). 2020; 11(2). PMC: 7073558. DOI: 10.3390/genes11020212. View

Goto Y, Nonaka I, Horai S . A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990; 348(6302):651-3. DOI: 10.1038/348651a0. View

Russell O, Fruh I, Rai P, Marcellin D, Doll T, Reeve A . Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo. Sci Rep. 2018; 8(1):1799. PMC: 5789095. DOI: 10.1038/s41598-018-20064-2. View

Pagliarini D, Calvo S, Chang B, Sheth S, Vafai S, Ong S . A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008; 134(1):112-23. PMC: 2778844. DOI: 10.1016/j.cell.2008.06.016. View

Zekonyte U, Bacman S, Smith J, Shoop W, Pereira C, Tomberlin G . Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo. Nat Commun. 2021; 12(1):3210. PMC: 8163834. DOI: 10.1038/s41467-021-23561-7. View

Taylor R, Schaefer A, McFarland R, Maddison P, Turnbull D . A novel mitochondrial DNA tRNA(Ile) (A4267G) mutation in a sporadic patient with mitochondrial myopathy. Neuromuscul Disord. 2002; 12(7-8):659-664. DOI: 10.1016/s0960-8966(02)00026-3. View

10.

Hatakeyama H, Katayama A, Komaki H, Nishino I, Goto Y . Molecular pathomechanisms and cell-type-specific disease phenotypes of MELAS caused by mutant mitochondrial tRNA(Trp). Acta Neuropathol Commun. 2015; 3:52. PMC: 4546323. DOI: 10.1186/s40478-015-0227-x. View

11.

Wei Y, Xu C, Feng H, Xu K, Li Z, Hu J . Human cleaving embryos enable efficient mitochondrial base-editing with DdCBE. Cell Discov. 2022; 8(1):7. PMC: 8803867. DOI: 10.1038/s41421-021-00372-0. View

12.

Young M, Larson D, Sun C, George D, Ding L, Miller C . Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell. 2012; 10(5):570-82. PMC: 3348423. DOI: 10.1016/j.stem.2012.03.002. View

13.

Carelli V, Chan D . Mitochondrial DNA: impacting central and peripheral nervous systems. Neuron. 2014; 84(6):1126-42. PMC: 4271190. DOI: 10.1016/j.neuron.2014.11.022. View

14.

Folmes C, Nelson T, Martinez-Fernandez A, Arrell D, Lindor J, Dzeja P . Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011; 14(2):264-71. PMC: 3156138. DOI: 10.1016/j.cmet.2011.06.011. View

15.

Workman M, Mahe M, Trisno S, Poling H, Watson C, Sundaram N . Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med. 2016; 23(1):49-59. PMC: 5562951. DOI: 10.1038/nm.4233. View

16.

Invernizzi F, DAmato I, Jensen P, Ravaglia S, Zeviani M, Tiranti V . Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells. Mitochondrion. 2012; 12(2):328-35. PMC: 3314980. DOI: 10.1016/j.mito.2012.01.001. View

17.

Pavlakis S, Phillips P, DiMauro S, De Vivo D, Rowland L . Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984; 16(4):481-8. DOI: 10.1002/ana.410160409. View

18.

Mok B, de Moraes M, Zeng J, Bosch D, Kotrys A, Raguram A . A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583(7817):631-637. PMC: 7381381. DOI: 10.1038/s41586-020-2477-4. View

19.

Lei Z, Meng H, Liu L, Zhao H, Rao X, Yan Y . Mitochondrial base editor induces substantial nuclear off-target mutations. Nature. 2022; 606(7915):804-811. DOI: 10.1038/s41586-022-04836-5. View

20.

Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T . Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499(7459):481-4. DOI: 10.1038/nature12271. View